Precision-targeted therapy via antibody drugs has become central to the field of cancer immunotherapy. Monoclonal antibodies ...

The full article, titled “A Potency-optimized CD28-activating Bispecific Antibody for the Targeted Treatment of Nectin-4 Positive Cancers,” is available online at JITC. Key findings for RNDO-564 ...

The company will provide an update on its lead program, RNDO-564, a co-stimulatory T-cell engaging bispecific antibody targeting CD28 and Nectin-4 for the treatment of bladder cancer.

CAR-T cell therapies are transforming the treatment of previously incurable blood cancers, ... and anti-CD3 and anti-CD28, two antibodies that, ...

First, the researchers determined optimal anti-CD3:anti-CD28 antibody ratios and quantities in TES that helped recruit maximum numbers of cultured CAR-T cells and induce them to become "effector T ...

Overview of the CAR-T cell therapy process, highlighting the sequential steps from leukapheresis to CAR-T cell infusion. (1) T cells are isolated from the patient's peripheral blood through ...

Rondo Therapeutics and Lilly partner on CD28 co-stimulatory bispecific antibodies for solid tumors. Dec. 5, 2024. The collaboration will combine Rondo’s proprietary CD28 co-stimulatory platform with ...

CAR-T cell therapies are transforming the treatment of previously incurable blood cancers, ... This lipid layer presents two antibody molecules, anti-CD3 and anti-CD28, ...